- Home
- IONS vs GTLB Comparison
IONS vs GTLB Comparison
Compare IONS & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- GTLB
- Stock Information
- Founded
- IONS 1989
- GTLB 2011
- Country
- IONS United States
- GTLB United States
- Employees
- IONS N/A
- GTLB N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- GTLB EDP Services
- Sector
- IONS Health Care
- GTLB Technology
- Exchange
- IONS Nasdaq
- GTLB Nasdaq
- Market Cap
- IONS 6.9B
- GTLB 7.2B
- IPO Year
- IONS 1991
- GTLB 2021
- Fundamental
- Price
- IONS $43.78
- GTLB $44.28
- Analyst Decision
- IONS Buy
- GTLB Buy
- Analyst Count
- IONS 14
- GTLB 26
- Target Price
- IONS $58.43
- GTLB $64.27
- AVG Volume (30 Days)
- IONS 2.0M
- GTLB 3.9M
- Earning Date
- IONS 07-30-2025
- GTLB 09-02-2025
- Dividend Yield
- IONS N/A
- GTLB N/A
- EPS Growth
- IONS N/A
- GTLB N/A
- EPS
- IONS N/A
- GTLB 0.08
- Revenue
- IONS $944,050,000.00
- GTLB $804,571,000.00
- Revenue This Year
- IONS $9.21
- GTLB $26.38
- Revenue Next Year
- IONS $14.35
- GTLB $21.20
- P/E Ratio
- IONS N/A
- GTLB $561.31
- Revenue Growth
- IONS 16.05
- GTLB 29.31
- 52 Week Low
- IONS $23.95
- GTLB $37.90
- 52 Week High
- IONS $50.43
- GTLB $74.18
- Technical
- Relative Strength Index (RSI)
- IONS 60.61
- GTLB 52.54
- Support Level
- IONS $40.37
- GTLB $38.81
- Resistance Level
- IONS $41.93
- GTLB $41.57
- Average True Range (ATR)
- IONS 1.42
- GTLB 2.10
- MACD
- IONS -0.03
- GTLB -0.14
- Stochastic Oscillator
- IONS 66.61
- GTLB 54.05
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About GTLB GitLab Inc.
GitLab Inc operates on an all-remote model. GitLab, a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, and Asia Pacific. It focused on accelerating innovation and broadening the distribution of its platform to companies across the world.